Method for testing peritoneal dissemination of gastric cancer by expression level of syt13, syt8, or anos1, test kit, method for screening molecularly targeted therapeutic agent, and therapeutic agent
US-2019024179-A1 · Jan 24, 2019 · US
Method for preventing or treating cancer using SYT11 inhibitor
US12397011B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12397011-B2 |
| Application number | US-202117234455-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2021 |
| Priority date | Oct 19, 2018 |
| Publication date | Aug 26, 2025 |
| Grant date | Aug 26, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a gastric cancer in a subject, comprising administering a Synaptotagmin 11 (SYT11) nucleic acid inhibitor to the subject, wherein the SYT11 inhibitor is selected from a group consisting of: siRNA, shRNA and an antisense oligonucleotide; and wherein the siRNA and shRNA inhibit expression of the SYT11 mRNA, and the antisense oligonucleotide reduces the expression of the SYT 11 protein. 2. The method of claim 1 , wherein the siRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. 3. The method of claim 1 , wherein the shRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17. 4. The method of claim 1 , wherein the antisense nucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 18 and SEQ ID NO: 19. 5. The method of claim 1 , wherein the gastric cancer is gastric cancer having a stem-like or mixed subtype.
Assignees
Inventors
Classifications
involving compounds localised on the membrane of tumour or cancer cells · CPC title
- G01N33/5753Primary
of the stomach or small intestine · CPC title
involving cells · CPC title
for testing antineoplastic activity · CPC title
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12397011B2 cover?
- The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.
- Who is the assignee on this patent?
- Korea Res Inst Bioscience & Biotechnology, Univ Yonsei Iacf
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5753. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).